Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Refortrix
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Refortrix is a vaccine manufactured by GlaxoSmithKline (GSK) containing reduced diphtheria toxoid, tetanus toxoid, and acellular pertussis components. It is designed to prevent three bacterial infections: **diphtheria**, **tetanus**, and **pertussis** (whooping cough). Administered via intramuscular injection, it is primarily used as a **booster vaccine for adults**. Refortrix is part of GSK's bacterial vaccines class and functions as an immunostimulant.
- Brand names
- Refortrix
- Other names
- BoostrixdTpa Booster VaccineTetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)PRN (Pertactin)
Beyond the preview
Go deeper on Refortrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Refortrix.